AbbVie Inc. (ABBV)
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.
Wall Street Brunch: Trump 'Fine' After Shooting
Trump confirms he is "fine" after assassination attempt during rally in Pennsylvania, suspect dead. Global leaders condemn violence, wish Trump speedy recovery.
3 Dividend Growth Stocks to Buy and Hold
AbbVie is poised to keep a 52-year streak of dividend hikes going. Amgen offers more than a dividend with its promising pipeline.
3 High-Yield Dividend Stocks That Still Look Like Bargains
Johnson & Johnson and AbbVie produce reliable earnings driven by sales of patent-protected drugs. Real estate investment trust Agree Realty makes monthly dividend payments.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.
5 High-Yield Dividend Champions to Buy Hand Over Fist Now
Dividend stocks are a favorite among investors for good reasons.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Smartest Dividend Stocks to Buy With $250 Right Now
One of these stocks is a Dividend King poised to deliver solid growth for years to come. Another offers an ultra-high dividend yield of 9.2% and has a big growth opportunity.
If I Had To Invest $100,000 In Dividend Aristocrats
If I had to invest $100K today in Dividend Aristocrats, here's what I would do. I'd spread my investments in between my top 10 picks within the list. I show you what portfolio profile this would create, and where it falls short.
AbbVie Q2 Preview: Upgrade To Buy - Better Late Than Never
AbbVie continues to navigate Humira's LOE brilliantly, with the higher rebates and lower pricing ensuring its market-leading share despite the notable impacts on the top/bottom lines. The management has also raised their FY2024 guidance despite the multiple adjustments related to the acquired IPR&D and milestones expenses. These developments underscore ABBV's robust ex-Humira portfolio growth and M&A acumen, building upon the +15% YoY growth reported in FQ1'24.
AbbVie cuts 2024 profit forecast on acquisition-related expenses
AbbVie on Wednesday lowered its 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in acquisition-related expenses.
AbbVie Stock: A Perfect Dip for Investors to Buy
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.
